{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:00:31Z","timestamp":1794470431149,"version":"4.9.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["2014SGR364"],"award-info":[{"award-number":["2014SGR364"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["290002"],"award-info":[{"award-number":["290002"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiviral immune responses present a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive tumor environment, adenovirus-infected cells can nonetheless be efficiently cleared by infiltrating cytotoxic T lymphocytes (CTL) without compromising tumor burden. In this study, we tested the hypothesis that tumor-infiltrating T cells could be more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T-cell\u2013engager (BiTE) antibodies. The oncolytic adenovirus ICOVIR-15K was engineered to express an EGFR-targeting BiTE (cBiTE) antibody under the control of the major late promoter, leading to generation of ICOVIR-15K-cBiTE, which retained its oncolytic properties in vitro. cBiTE expression and secretion was detected in supernatants from ICOVIR-15K-cBiTE\u2013infected cells, and the secreted BiTEs bound specifically to both CD3+ and EGFR+ cells. In cell coculture assays, ICOVIR-15K-cBiTE\u2013mediated oncolysis resulted in robust T-cell activation, proliferation, and bystander cell-mediated cytotoxicity. Notably, intratumoral injection of this cBiTE-expressing adenovirus increased the persistence and accumulation of tumor-infiltrating T cells in vivo, compared with the parental virus lacking such effects. Moreover, in two distinct tumor xenograft models, combined delivery of ICOVIR-15K-cBiTE with peripheral blood mononuclear cells or T cells enhanced the antitumor efficacy achieved by the parental counterpart. Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limitations in oncolytic virotherapy. Cancer Res; 77(8); 2052\u201363. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-16-1708","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T21:05:20Z","timestamp":1485896720000},"page":"2052-2063","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy"],"prefix":"10.1158","volume":"77","author":[{"given":"Carlos Alberto","family":"Fajardo","sequence":"first","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Guedan","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alfonso","family":"Rojas","sequence":"additional","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Moreno","sequence":"additional","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Arias-Badia","sequence":"additional","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"de Sostoa","sequence":"additional","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[{"name":"1ProCure Program, IDIBELL-Institut Catal\u00e0 d'Oncologia, L'Hospitalet de Llobregat, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"2022061706191409600_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotech"},{"key":"2022061706191409600_bib2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: from bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2022061706191409600_bib3","doi-asserted-by":"crossref","first-page":"e28694","DOI":"10.4161\/onci.28694","article-title":"Trial Watch","volume":"3","author":"Pol","year":"2014","journal-title":"OncoImmunology"},{"key":"2022061706191409600_bib4","first-page":"51","article-title":"Mechanisms of Immune Evasion by Tumors","volume-title":"Advances in immunology","author":"Drake","year":"2006"},{"key":"2022061706191409600_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2022061706191409600_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/hum.2009.143","article-title":"Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus","volume":"21","author":"Galivo","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2022061706191409600_bib7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/gt.2015.41","article-title":"Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity","volume":"22","author":"Rodriguez-Garcia","year":"2015","journal-title":"Gene Ther"},{"key":"2022061706191409600_bib8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/1097-0142(195611\/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7","article-title":"Studies on the use of viruses in the treatment of carcinoma of the cervix","volume":"9","author":"Smith","year":"1956","journal-title":"Cancer"},{"key":"2022061706191409600_bib9","first-page":"265","article-title":"Chapter Eight - Oncolytic Adenoviruses for Cancer Immunotherapy: Data from Mice, Hamsters, and Humans","volume-title":"Advances in cancer research","author":"Cerullo","year":"2012"},{"key":"2022061706191409600_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming oncolytic viruses to leverage antitumor immunity","volume":"15","author":"de Gruijl","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"2022061706191409600_bib11","first-page":"22","article-title":"BiTE: Teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"2022061706191409600_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs \u2013 past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol Rev"},{"key":"2022061706191409600_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","article-title":"Targeting T cells to tumor cells using bispecific antibodies","volume":"17","author":"Frankel","year":"2013","journal-title":"Curr Opin Chem Biol"},{"key":"2022061706191409600_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol Ther"},{"key":"2022061706191409600_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00109-007-0291-1","article-title":"Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer","volume":"86","author":"Nettelbeck","year":"2008","journal-title":"J Mol Med"},{"key":"2022061706191409600_bib16","first-page":"733","article-title":"Pharmacy and Therapeutics","volume":"39","author":"New Drugs\/Drug News","year":"2014"},{"key":"2022061706191409600_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia","volume":"24","author":"Barrett","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2022061706191409600_bib18","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"2022061706191409600_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/gt.2011.106","article-title":"Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD","volume":"19","author":"Rojas","year":"2012","journal-title":"Gene Ther"},{"key":"2022061706191409600_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2009.038","article-title":"Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting","volume":"20","author":"Bayo-Puxan","year":"2009","journal-title":"Hum Gene Ther"},{"key":"2022061706191409600_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"key":"2022061706191409600_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/gt.2014.52","article-title":"iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy","volume":"21","author":"Puig-Saus","year":"2014","journal-title":"Gene Ther"},{"key":"2022061706191409600_bib23","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1158\/0008-5472.CAN-08-1145","article-title":"Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency","volume":"68","author":"Gros","year":"2008","journal-title":"Cancer Res"},{"key":"2022061706191409600_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"key":"2022061706191409600_bib25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol Ther"},{"key":"2022061706191409600_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/cgt.2013.85","article-title":"The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model","volume":"21","author":"Puig-Saus","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"2022061706191409600_bib27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunother"},{"key":"2022061706191409600_bib28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"M\u00f8lh\u00f8j","year":"2007","journal-title":"Mol Immunol"},{"key":"2022061706191409600_bib29","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"2022061706191409600_bib30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022061706191409600_bib31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706191409600_bib32","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"107","author":"Lutterbuese","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"2022061706191409600_bib33","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"2022061706191409600_bib34","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"2022061706191409600_bib35","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol Ther"},{"key":"2022061706191409600_bib36","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/mt.2008.141","article-title":"The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens","volume":"16","author":"Schirmbeck","year":"2008","journal-title":"Mol Ther"},{"key":"2022061706191409600_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"2022061706191409600_bib38","doi-asserted-by":"crossref","first-page":"e1105429","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"OncoImmunology"},{"key":"2022061706191409600_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","article-title":"Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy","volume":"60","author":"Carretero","year":"2008","journal-title":"Immunogenetics"},{"key":"2022061706191409600_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"2022061706191409600_bib41","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2326-6066.CIR-15-0037","article-title":"Committing cytomegalovirus-specific CD8 T cells to eliminate tumor cells by bifunctional major histocompatibility class I antibody fusion molecules","volume":"3","author":"Schmittnaegel","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061706191409600_bib42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol Ther"},{"key":"2022061706191409600_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2967\/jnumed.115.168153","article-title":"Biodistribution and PET imaging of labeled bispecific T cell\u2013engaging antibody targeting EpCAM","volume":"57","author":"Warnders","year":"2016","journal-title":"J Nucl Med"},{"key":"2022061706191409600_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0168-1656(01)00355-8","article-title":"Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein","volume":"92","author":"W\u00fcest","year":"2001","journal-title":"J Biotechnol"},{"key":"2022061706191409600_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.virol.2004.06.043","article-title":"Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-\u03b1","volume":"328","author":"Engler","year":"2004","journal-title":"Virology"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/8\/2052\/2765543\/2052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/8\/2052\/2765543\/2052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:23:29Z","timestamp":1655475809000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/8\/2052\/626156\/Oncolytic-Adenoviral-Delivery-of-an-EGFR-Targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-1708","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6509795.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22417247.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22417247","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}